Atrium Therapeutics, Inc. Stock Analysis & AI Score
Atrium Therapeutics, Inc. (RNA) has an ST Score of 45.8 (C+), driven by its Forecast (A) and held back by its Growth (F). Analysts rate it Buy with a $25.00 price target (+205.3% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Atrium Therapeutics, Inc. (RNA) has an ST Score of 45.8 (C+), driven by its Forecast (A) and held back by its Growth (F). Analysts rate it Buy with a $25.00 price target (+205.3% upside).
- Strongest
- ForecastA
- Weakest
- GrowthF
All factor grades
- ForecastA
- Financial StrengthA-
- ProfitabilityB-
- ValuationC-
- MomentumD
- GrowthF
Contact
RNA stock: frequently asked questions
What is RNA's ST Score?
Atrium Therapeutics, Inc. (RNA) has an ST Score of 45.8 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is RNA a buy, hold, or sell?
Analysts rate RNA a Buy, with a price target of $25.00 (+205.3% vs the current price). Our ST Score grades it C+ (45.8/100). The ST Score is a data-driven signal, not a recommendation.
What are RNA's factor grades?
Valuation C-, Profitability B-, Financial Strength A-, Momentum D, Growth F, Forecast A.
What is RNA's valuation grade?
Atrium Therapeutics, Inc. (RNA) earns a valuation grade of C-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is RNA's growth grade?
Atrium Therapeutics, Inc. (RNA) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is RNA's profitability grade?
Atrium Therapeutics, Inc. (RNA) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is RNA's financial strength grade?
Atrium Therapeutics, Inc. (RNA) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for RNA?
The average analyst price target for Atrium Therapeutics, Inc. (RNA) is $25.00 from 16 analysts, which is +205.3% versus the recent price of $8.19.